GDM Patients and Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist

Study Overview
=================
Brief Summary
-----------------
Serum amyloid A and Interleukin-1 (IL-1) receptor antagonist (A-SAA and IL-1Ra) values; Comparison of pregnant women with and without GDM diagnosis Comparison of insulin therapy and diet-regulated GDM patients Comparison of pregnant women with and without LGA (large gestational age) Comparison of pregnant women with and without polyhydroamnios Investigation of its effect on pregnancy prognosis In the prediction of GDM diagnosis, it is aimed to study the sensitivity and specificity of both parameters and cut off values. (In GDM patients, liver and kidney function parameters will also be evaluated with A-SAA and IL-1Ra levels).

Official Title
-----------------
Levels of New Inflammatory Markers in GDM Patients; Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist

Conditions
-----------------
Gestational Diabetes

Intervention / Treatment
-----------------
* Diagnostic Test: Serum amyloid A values
* Diagnostic Test: Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with 50 gr OGTT + 100 gr OGTT + at 24-28 weeks of gestation Patients with 75 gr OGTT + at 24-28 weeks of gestation 18-42 years pregnant women Exclusion Criteria: any infection Any known fetal chromosomal or structural anomaly Preterm membrane rupture Preterm delivery Preeclampsia or eclampsia Placenta previa

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 42 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| study group ; Patients with gestational diabetes<br>Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees. | Diagnostic Test: Serum amyloid A values<br>* Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.<br>Diagnostic Test: Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)<br>* Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.<br>|
| control group ; healthy pregnant women<br>Women who are healthy pregnant women, the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees. | Diagnostic Test: Serum amyloid A values<br>* Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum amyloid A | Its level will be checked in the study group consisting of pregnant women with GDM and in the control group consisting of healthy pregnant women. | 1 week | 
| Interleukin-1 (IL-1) receptor antagonist | Its level will be checked in the study group consisting of pregnant women with GDM and in the control group consisting of healthy pregnant women. | 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gestational Diabetes, Serum amyloid A, Interleukin-1 (IL-1) receptor antagonist